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ABSTRACT
Objective: The present research study was undertaken to formulate mucoadhesive sustained release buccal tablets and patches of 5-fluorouracil 
(5-FU).
Method: For the research experiment work design expert software version 10, stat-ease, Inc. has been used. A 32 full factorial design was selected 
for the formulation of the buccal tablet as well as buccal patches. In this research work, formulated tablets and patches using different polymers such 
as carbopol 974p, polyvinylpyrrolidone-K 30, sodium deoxycholate, microcrystalline cellulose, and polyvinyl alcohol. An after formulation of batches 
formulated products studied for characterization, namely, Fourier transform infrared (FTIR) and differential scanning calorimeter (DSC). Evaluation 
parameters studied such as weight uniformity, thickness, hardness, friability, and content uniformity also carried out. For drug release purpose from 
the formulation of buccal tablet and patches in vitro drug released performed. In vivo drug releases study also carried out using Rabbit for drug 
reaction point of view.
Results: Design expert showed the significant results on independent and dependent variables. The R-Squared 0.9943 for drug release and 0.9985 
for swelling index is in reasonable agreement with the formulations. FTIR and DSC indicating compatibility of the drug and polymers in the tablet 
formulation and patch formulations at the molecular level. The drug release of buccal tablet showed 75.10–99.34% and buccal patches showed 
58.41–81.43%. These formulations showed good results when compared to the conventional tablet.
Conclusion: Formulation of mucoadhesive sustained release buccal tablets and patches of 5-FU successfully done using different polymers, which 
would definitely help in increasing bioavailability of the drug.
Keywords: Mucoadhesive sustained release, 5-Fluorouracil, Carbopol 974p, Polyvinylpyrrolidone-K 30, In vitro drug release, In vivo drug release.
INTRODUCTION
Among the various routes of drug delivery, the oral route is perhaps 
the most preferred to the patient and the clinician alike. However, 
administration of drugs has disadvantages such as hepatic first pass 
metabolism and enzymatic degradation within the gastrointestinal (GI) 
tract, that prohibit oral administration of certain classes of drugs [1]. 
Bioadhesive drug delivery formulations were introduced in 1947 when 
gum tragacanth was mixed with dental adhesive powder to apply 
penicillin to the oral mucosa [2]. Buccal delivery of drugs provides an 
attractive alternate to other conventional methods of systemic drug 
administration since buccal mucosa is relatively permeable with rich 
blood supply and acts as an excellent site for the absorption of drugs. 
The administration of drugs through buccal route facilitate a direct entry 
of drug molecules into the systemic circulation, avoiding the first-pass 
metabolism and drug degradation in the harsh GI environment, which 
are often associated with oral administration. The buccal cavity is easily 
accessible for self-medication, and hence, it is safe and well accepted 
by patients since buccal patches can be very easily administered and 
even removed from the application site, terminating the input of drug 
whenever desired. Moreover, buccal patches provide more flexibility 
than other drug deliveries [3]. Bioadhesion can be defined as a 
phenomenon of interfacial molecular attractive forces in the middle 
of the surfaces of the biological substrate and the natural or synthetic 
polymers, which allows the polymer to adhere to the biological surface 
for an extended period [4].
The oral mucosa has many properties, which not only makes it an 
attractive site for drug delivery but also provides several challenges for 
researchers investigating novel delivery techniques to overcome many 
different formulations including sprays, tablets, mouthwashes, gels, 
pastes, and patches are presently used for delivery into and/or across 
the oral mucosa [5].
In recent years, delivery of therapeutic agents through mucoadhesive 
drug delivery system has become highly interesting. Certain drugs have 
the lack of efficacy due to decreased bioavailability, GI intolerance, 
unpredictable, and erratic absorption or presystemic elimination of 
other potential route for administration. The recent development in 
the drug delivery has intensified the investigation of mucosal drug 
delivery. Such route includes oral, buccal, ocular, nasal, and pulmonary 
routes, etc. Mucoadhesive drug delivery systems are delivery systems, 
which utilized the property of bioadhesion of certain polymers, which 
become adhesive on hydration and hence can be used for targeting 
a drug to a particular region of the body for an extended period. The 
ability to maintain a delivery system at a particular location for an 
extended period has great appeal for both local as well as systemic drug 
bioavailability. Pharmaceutical aspects of mucoadhesion have been the 
subject of great interest during recent years because it provides the 
possibility of avoiding either destruction by GI contents or hepatic first-
pass inactivation of the drug [6,7].
5-Fluorouracil (5-FU) is a medication used to treat cancer. By injection 
into a vein, it is used for colon cancer, esophageal cancer, stomach 
cancer, pancreatic cancer, breast cancer, and cervical cancer. When 
used by injection most people develop side effects. Common side 
effects include inflammation of the mouth, loss of appetite, low blood 
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cell counts, hair loss, and inflammation of the skin [8]. When used as a 
cream irritation at the site of application may occur [9]. The use of either 
form in pregnancy may harm the baby. FU is in the antimetabolite and 
pyrimidine analog families of medications [10,11]. How it works is not 
entirely clear but believed to involve blocking the action of thymidylate 
synthase and thus stopping the production of DNA. FU has been 
given systemically for anal, breast, colorectal, esophageal, stomach, 
pancreatic, and skin cancers (especially head-and-neck cancers). It 
has also been given topically (on the skin) for actinic keratoses, skin 
cancers, and Bowen’s disease [12] and as eye drops for the treatment of 
ocular surface squamous neoplasia [13].
The present research study was undertaken to formulate mucoadhesive 




5-FU, polyvinyl alcohol, talc, and sodium deoxycholate was procured 
from ozone international, Mumbai. Carbopol 974p, polyvinylpyrrolidone 
K30 was procured from Wockhardt Ltd, Aurangabad. Microcrystalline 
cellulose was procured from RanQ remedies Pvt. Ltd., Pune. All other 
ingredients were used for laboratory scale.
Methods
Formulation and preparation of mucoadhesive buccal tablets of 
5-FU
The mucoadhesive buccal tablets were prepared by a direct compression 
method using direct compression (Cadmach, Ahmadabad). The 
mucoadhesive drug/polymer mixture was prepared by homogeneously 
mixing the carbopol 974P, polyvinylpyrrolidone (PVP) K-30, complex 
(CP+PVP), sodium deoxycholate, microcrystalline cellulose, and Talc. 
All the ingredients of the mucoadhesive buccal tablet of 5-FU were 
weighed (Table 1) sifted and mixed in mortar with the help of pastel. 
The 150 mg mixture was then compressed using 8 mm punch in a single 
stroke on single punch tablet machine. Each tablet weighed 150 mg [14].
Experimental design
For the research experiment work design expert software version 10, 
stat-ease, Inc. has been used. A 32 full factorial design was selected 
because an experiment may be designed to focus attention on a single 
independent variable or factor. An alternative approach is to study the 
influence of one independent variable in conjunction with variations 
in one or more additional independent variables. In this research 
study, not only the effects of the two independent variables separately 
but also how they combine to influence the dependent variable. The 
amount of carbopol (X1) and the amount of polyvinylpyrrolidone (X2) 
were selected as independent variables. Two-factor (X1, X2), three-
level (−1, 0, +1) design can be developed. Two-factor were evaluated 
each at three-level, and experimental trials were performed for all nine 
possible combinations. In vitro drug release and mucoadhesion were 
selected as dependent variables. The actual and coded formulation 
design of swellable gastro-retentive tablets according to factorial 
design (32) layout is shown in Tables 2 and 3 [15].
Formulation and preparation of mucoadhesive buccal patches of 
5-FU
The calculated amount of polymer was dissolved in distilled water with 
magnetic stirring for 24 h, and then, the drug (5-FU) was incorporated 
into the polymeric solution with continuous stirring. The desired 
quantity of the plasticizer (propylene glycol) was added and kept aside 
for 1 h at room temperature. The mixture of the polymeric solution and 
drug of all formulas was poured on aluminum foil in a glass petri dish 
having 15 cm diameter. The petri dishes were kept on leveled surface 
and covered by inverted funnel to allow controlled evaporation of 
solvent at room temperature until a flexible patch was formed. Dried 
patches were carefully removed, checked for any imperfections or air 
bubbles and cut into small patches. The patch was packed in aluminum 
foil and stored in desiccator to maintain the integrity and elasticity 
of the patches. The composition of buccoadhesive patches is listed in 
Table 4 [16].
Characterization
Fourier transform infrared (FTIR)
The FTIR (IR-Affinity 1S, Shimadzu) spectra of drug, polymers, and 
formulations were recorded using KBr pellet method. The materials 
were triturated in porcelain mortar pestle with dry potassium bromide 
in the ratio (1:100). The pellets were prepared in KBr press at pressure 
8 tones. The pellet was scanned over the range of 4000–600/cm and the 
spectra obtained were reported [17].
Differential scanning calorimeter (DSC)
DSC was performed on drug, polymers, and formulations. The physical 
mixtures of drug, polymers, and formulations were prepared by 
triturating (1:1) in a dried mortar for 5 min and kept as it is for 24 h. 
The materials were weighed, 2–7 mg and sealed in aluminum pans. The 
sealed aluminum pan was heated at a scanning rate of 20°C/min over a 
temperature range of 90 to 300°C. Empty aluminum pan was used as a 
reference. The heat flow as a function of temperature was measured for 
the drug, and drug-polymer mixture [18].
Evaluation parameters for buccoadhesive dosage form
Uniformity weight of tablet and patch
Twenty tablets were selected at random from each batch, weighed 
individually, and the average weight was calculated. The batch passes 
the test for uniformity of weight if not more than two of the individual 
tablet weight deviates from the average weight by more than the 7.5% 
as shown in Table 5.
Each patch was weighed individually on an analytical balance (Shimadzu.
AUX220, Japan) and the average weights were calculated [19,20].
Thickness
The thicknesses of buccal tablets were determined using digital vernier 
caliper (Mitutoyo, Japan) and the average was calculated. Ten individual 
tablets and patches from each batch were used and the average 
thickness was calculated [21].
Friability
The friability of the 6 tablets was determined using Roche friabilator 
(Electrolab, Mumbai). This device subjects the tablets to the combined 
effect of abrasion sand shock in a plastic chamber revolving at 25 rpm 
and dropping the tablets at a height of 6 inches in each revolution. 
Preweighed sample of tablets was placed in the friabilator and were 
subjected to 100 revolutions [22]. Tablets were de-dusted using a soft 
muslin cloth and reweighed. The friability (F) is given by the formula:
F=(1−W0/W)×100 Eq. (1)
Where,
W0 is the weight of the tablets before the test
W is the weight of the tablet after the test.
Hardness
Pfizer hardness tester (Monsanto Rolex) was used for the determination 
of the tablets hardness. For each formulation the hardness of 6 tablets 
was evaluated [22].
Surface pH study
The surface pH of the buccal tablet was determined in order to 
investigate the possibility of any side effects in vivo. As an acidic or 
alkaline pH may irritate the buccal mucosa, we sought to keep the 
surface pH as close to neutral as possible. A combined glass electrode 
was used for this purpose. The tablet was allowed to swell by keeping 
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it in contact with 1 mL of phosphate buffer (pH 6.8) for 2 h at room 
temperature. The pH was identified by bringing the electrode into 
contact with the tablet surface and allowing the surface to equilibrate 
for 1 min [23,24].
Swelling study
Buccal tablets and patches were weighed individually; initial weight 
was considered as W1 and placed separately in Petri dishes containing 
10 mL of phosphate buffer (pH 6.8) solution in such a way that the 
side of tablet and patch, which attaches to the buccal membrane was 
positioned to the bottom of the petri dishes with the backing membrane 
being viewable from the top. Tablets and patches were soaked in such 
a way that they completely immersed in the buffer solution. At time 
intervals of 12 h, the buccal tablets and patch were removed from the 
petri dishes using coverslips and excess surface water was removed 
carefully using the Whatman filter paper. The swollen tablets and 
patches were then reweighed (W2). This experiment was performed in 
triplicate [25]. The degree of swelling (water uptake) was calculated 
according to the following formula:
Degree of swelling 







Five tablets were selected at random and were powdered in a mortar; 
and the amount of powder equivalent to single dose was dissolved in 
phosphate buffer pH 6.8 up to 10 ml by sonication (Dolphin, Mumbai) 
for 15 min and filtered through Whatman filter (0.45 µm) paper. The 
drug content was analyzed spectrophotometrically at 261.4 nm using 
a UV spectrophotometer (Shimadzu 1601). Each measurement was 
carried out in triplicate and the average drug content was calculated.
Drug content uniformity was determined by dissolving the patch in 
100 ml of phosphate buffer (pH 6.8) for 24 h with stirring. From the 
solution 5 ml was diluted with the drug content was then determined 
after proper dilution of the filtered solution at 266 nm using a UV 
spectrophotometer [26].
Ex vivo mucoadhesive strength and force of adhesion
A modified balance method was used for determining the ex vivo 
mucoadhesion strength. Goat buccal mucosa was used as the model 
substrate, and phosphate buffer pH 6.8 was used as the moistening 
fluid. Freshly excised goat buccal mucosa was obtained from the local 
slaughterhouse used within 3 h of slaughter. The tablet and patch were 
laid onto the model membrane under a manual pressure of 5 min. 
Bioadhesive strength was measured in terms of weight in grams of water 
required to detach the tablet and patch from the goat buccal mucosa. 
The addition of water was stopped when tablet and patch was detached 
from goat buccal mucosa. The weight of water required to detach the 
tablet and patch, respectively, from buccal mucosa was noted as ex 
vivo mucoadhesive strength. Mucoadhesive strength was performed in 
duplicate, and average mucoadhesive strength was determined [23]. 
From this mucoadhesive strength, the force of adhesion was calculated 
using the following formula.
Force of adhesion N
Mucoadhesive strength( ) = ×
100
9 81.  Eq. (3)
Ex vivo mucoadhesive time
The ex vivo mucoadhesion time studies were performed after application 
of tablet and patch, respectively, on freshly cut goat stomach mucosa. 
The mucosa was fixed on a glass slide using double-sided adhesive, 
and one side of glass slide was fixed to thread whose another end was 
fixed with the arm of tablet disintegration test apparatus. A side of each 
tablet and patch was wetted with dissolution medium and was attached 
to the mucosa by applying a light force with a fingertip for 20 s. The 
beaker was filled with 800 mL of phosphate buffer of pH 6.8 maintained 
at 37±0.50°C were used as disintegration medium and after 2 min the 
slide was placed in a beaker, and the apparatus was started. Care was 
taken that while up and down motion of the arm tablet and patch should 
remain in the medium. Behavior and mucoadhesive time of tablet and 
patch were monitored until complete detachment occurred [21].
Folding endurance
Randomly selected three films from each batch were taken to measure 
the folding endurance. The films were repeatedly folded at the same 
place until it broke. The films folded up to 300 times manually was 
considered satisfactory value. The number of times of film could be 
folded at the same place without breaking gave the value of the folding 
endurance [27].
Table 1: Composition of 5-fluorouracil mucoadhesive buccal tablet
Ingredients (mg) Formulation batches
FT1 FT2 FT3 FT4 FT5 FT6 FT7 FT8 FT9
5-fluorouracil 20 20 20 20 20 20 20 20 20
Complex (CP+PVP) 80 80 80 80 80 80 80 80 80
Carbopol 5 12.5 5 5 12.5 20 20 12.5 20
Polyvinylpyrolidone 12.5 20 20 5 12.5 12.5 5 5 20
Sodium deoxycholate 3 3 3 3 3 3 3 3 3
Microcrystalline cellulose 5 5 5 5 5 5 5 5 5
Talc 5 5 5 5 5 5 5 5 5
PVP: Polyvinylpyrrolidone




Actual values (% w/w)




Table 3: Presentation of real values of 3 levels for the statistical 
design
S. No Batch Variable levels in coded form
Carbopol (X1) Polyvinylpyrrolidone (X2)
1 FT1 −1 0
2 FT2 0 1
3 FT3 −1 1
4 FT4 −1 −1
5 FT5 0 0
6 FT6 1 0
7 FT7 1 −1
8 FT8 0 −1
9 FT9 1 1
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Tensile strength (TS) measurement
Dried patch samples were cut into uniform strips (2.5 cm×5 cm). Two 
pieces of cardboard (1 cm×2.5 cm) were attached to the upper and the 
lower end of the patch using cyanoacrylate resin adhesive. Attaching the 
patch to the cardboard facilitates clamping it to the jaws of the modified 
device used for TS measurement, thus preventing pressure on the 
patches and slipping before or during application. The modified device 
contains a rectangular frame with two jaws made up of aluminum. 
One jaw is stationary in the front, and the other one is movable and 
can be pulled by loading weights on the pan attached with string to the 
movable part. The patch on the cardboard was clamped between the 
two jaws of the device positioned at a distance of 3 cm. The weights 
were gradually added to the pan until the patch was broken. The 
weight necessary to break the patch was noted as breaking force, and 
the simultaneous distance traveled by the pointer on the graph paper 
indicated the elongation at break (E/B) [28]. TS and percent elongation 
can be obtained by following formula:
Tensile strength 










= ×100  Eq. (5)
Ex vivo permeation study
Permeation study was carried out for the optimized formulation using 
Franz diffusion cell. The tablet and patches, respectively, were placed 
in the donor compartment on the sheep mucosa. The mucosal layer 
is on donor compartment. The receptor compartment was filled with 
phosphate buffer pH 6.8. The temperature was maintained at 37±0.5°C 
and 50 rpm. The amount of 5-FU permeated through sheep mucosa 
was determined by withdrawing 3 ml of aliquots from the receptor 
compartment using a syringe and immediately replacing the same 
volume of the solution [14].
In vitro drug release buccal tablets
The United States pharmacopoeia (USP) type ІІ dissolution apparatus 
(Veego Scientific DA6D, Mumbai) was used to study the release of drug 
from buccal tablets. Tablets were supposed to release the drug from one 
side only; therefore, an impermeable backing membrane was placed on 
the other side of the tablet. The tablet was further fixed to a 2 cm × 
2 cm glass slide with a solution of cyanoacrylate adhesive. In vitro drug 
release studies were carried out in 900 ml of phosphate buffer solution 
pH 6.8 for 10 h at 100 rpm and 37±0.5°C. At predetermined time 
intervals, 1 ml of samples were withdrawn and replaced with 1 ml fresh 
medium. The samples were filtered, diluted suitably then analyzed 
spectrometrically at 266 nm [28]. All dissolution was performed in 
triplicate.
In vitro drug release buccal patches
The drug release study from the patches was carried out using a USP 23 
Type 2 rotating paddle dissolution test apparatus (Electrolab). A total 
of 250 ml of solution (pH 6.8) at 37°C±5°C was used as the dissolution 
medium with a stirring rate of 50 rpm. A patch of 2.5 cm diameter was 
fixed onto a glass disc with the help of cyanoacrylate adhesive. The 
disc was put at the bottom of the dissolution vessel such that the patch 
remained on the upper side of the disc. Samples (5 ml) were withdrawn 
at a predetermined time interval of 30 min and replaced with an equal 
volume of dissolution medium. The samples were filtered through a 
0.45 mm filter and appropriately diluted with SHS solution (pH 6.8) and 
assayed spectrophotometrically at 266 nm [28]. The experiment was 
performed in triplicate, and average values were reported.
In vivo drug release study for tablets and films
Six male New Zealand white rabbits (2.6 kg) were selected for the 
in vivo study. The dose of 5-FU was adjusted based on the rabbit weight, 
and the optimized formulations were cut and placed in the buccal 
membrane with the help of a clip and tablets placed in the buccal 
membrane with the adhesive layer. Dextrose solution was transfused 
continuously throughout the period of the study. Periodically, 1 ml of 
blood sample was taken by syringe containing 1 ml of heparin solution 
to prevent blood clotting. These blood samples were centrifuged at 
2500 rpm for about 30 min. One milliliter of the supernatant was taken, 
and after suitable dilution analyzed at 266 nm spectrophotometrically 
by the method described under in vitro analysis [29,30].
Stability studies
Stability studies were carried out on the formulation, according to 
the ICH guidelines. The optimized formulations were selected, and 
the stability studies were carried out at the accelerated condition of 
40±2°C, 75±5% RH conditions, stored in desiccators, the formulations 
were packed in amber color screw cap container and kept in above-said 
condition for 3 months. The formulations were analyzed periodically 
for their physical appearance, buccoadhesive strength, and in vitro drug 
release [29,31].
RESULT AND DISCUSSION
Evaluation parameters for factorial batches (tablet formulation)
The evaluation parameters of tablets and patches are given in Tables 6 
and 7, respectively. The friability found in tablet formulations shows a 
good strength of tablets to withstand abrasion during transportation 
and general handling.
The hardness of all tablet batches was in the range of 3.1–4.2 kg/cm2. 
Such hardness range is enough to give mechanical strength indicating 
good compressibility of blends. The content uniformity of drug is found 
in tablet between 97.98–99.87% and 90–99% in patch formulation.
Table 4: Composition of preliminary batches for formulation of buccal patches
Ingredients FP-1 FP-2 FP-3 FP-4 FP-5 FP-6 FP-7 FP-8 FP-9
5-fluorouracil (mg) 200 200 200 200 200 200 200 200 200
Carbopol 974p (mg) 100 100 33.5 66.5 66.5 33.5 33.5 100 66.5
PVP k30 (mg) 33.5 100 66.5 33.5 100 33.5 100 66.5 66.5
PVA (g) 5 5 5 5 5 5 5 5 5
PEG (ml) 30 30 30 30 30 30 30 30 30
Ethanol (ml) 20 20 20 20 20 20 20 20 20
Water (ml) 150 150 150 150 150 150 150 150 150
PVP: Polyvinylpyrrolidone, PEG: Polyethylene glycol, PVA: Polyvinyl alcohol
Table 5: Limits of percentage deviation allowed underweight 
variation test
Average weight of tablet % Deviation
80 mg or less 10
80 mg <×<250 mg 7.5
250 mg or more 5
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Characterization
FTIR
The IR spectrum of pure drug, polymers and physical mixture are 
used to establish the characteristic behavior of the drug and in its 
formulations. The pure drug 5-FU Figs. 1a and 2a shows peaks at 
3500/cm to N-Hstretching, at 3100/cm to C-Hstretching (aromatic), 
at 2800/cm to C-Hstretching (aliphatic), at 1730/cm to C=Ostretching, 
at 930/cm to C-Fstretching. It is evident from the spectral study, that 
there is no difference worth mentioning in the portions of characteristic 
absorption bands of various functional groups and bonds present in the 
drug molecule and the formulations prepared from it. The drug has not 
lost its characteristic properties when it is converted into its different 
formulations. These observations support the fact that the drug has 
maintained its integrity in its formulations as it retained its physical 
characteristics without undergoing any change in its properties. This 
suggests that there is no interaction of the drug with polymer and 
excipients used in preparation of the formulations. Hence, it can be 
concluded that the drug has not under gone any type of interaction 
with the excipients used in the formulation development. From the 
result, it was observed that the entire characteristic peaks of 5-FU, were 
present in the tablet formulation and patch formulation spectrum. 
Thus, indicating compatibility of the drug and polymer in the tablet 
formulation and patch formulation at molecular level.
DSC
DSC thermogram of 5-FU pure drug and polymer was studied and it 
was found that drug 5-FU Fig. 3a shown endothermic peak at 283.17°C. 
Fig. 3b Carbopol 974p showed endothermic peak at 82.34°C, 142.87°C, 
204.90°C. Fig. 3c Polyvinylpyrolidone showed endothermic peak at 
96.94°C, 193.30°C, 253.71°C and Fig. 3d complex of Carbopol+PVP 
showed endothermic peak at 85.05°C, 161.92°C, and 238.66°C. This 
suggests that there is no interaction of the drug with polymer and 
excipients used in preparation of the formulations.
Mucoadhesive strength study and in vitro retention time of 5-FU 
buccal tablets
Carbopol and PVP have been reported to possess good mucoadhesive 
properties in buccal tablet formulations. When these polymers come 
in contact with water forms mucilage and swells, thus are responsible 
for mucoadhesion by simple bonding with mucus components. 
Mucoadhesion strength and mucoadhesion force were found good 
enough results, namely, 11.42–14.56 g and 1.079–1.428, respectively. 
Mucoadhesion time was found in the range of 7.5–11.10 h shown 
in Table 8. The results of mucoadhesion study indicate that it will 
definitely help to retain the tablet for longer period. The swelling 
of the polymers is studied by their ability to imbibe water and swell 




Weight uniformity (g) Thickness (mm) Hardness (kg/cm2) Friability (%) Content uniformity (%)
FT1 132.2±0.51 1.03 3.3±0.13 0.13 99.28±0.20
FT2 146.1±0.15 2.01 4.2±0.11 0.22 99.63±0.12
FT3 138.5±0.26 1.02 3.5±0.20 0.15 99.58±0.10
FT4 123.0±0.72 1.01  3.1±0.10 0.15 98.72±0.04
FT5 139.2±0.35 1.01 3.2±0.18 0.12 99.87±0.03
FT6 146.4±0.49 2.02 3.1±0.16 0.16 99.46±0.01
FT7 138.2±0.38 1.02 3.4±0.30 0.16 99.32±0.16
FT8 130.4±0.23 1.02 4.1±0.19 0.14 99.84±0.28
FT9 153.1±0.42 2.03 4.0±0.25 0.12 97.98±0.5










FP1 6.45±0.173 241±2.17 0.269±0.023 >290 90.3±1.02 3.22±0.56
FP2 6.11±0.173 245±6.42 0.289±0.025 >290 93.0±0.67 4.07±0.86
FP3 6.08±0.173 263±10.6 0.205±0.015 >290 98.3±0.12 4.28±0.46
FP4 6.36±0.208 278±4.25 0.260±0.015 >290 90.0±0.99 3.77±0.33
FP5 5.90±0.152 265±1.76 0.348±0.045 >290 96.4±0.56 3.77±0.33
FP6 7.06±0.200 212±5.78 0.256±0.025 >290 94.6±0.98 4.94±0.54
FP7 6.52±0.155 282±3.24 0.370±0.010 >290 99.0±0.19 3.55±0.99
FP8 5.98±0.251 269±2.65 0.234±0.011 >290 97.0±0.49 3.98±0.33
FP9 7.32±0.360 277±5.36 0.245±0.028 >290 96.3±0.85 4.57±0.33
*SD: Standard deviation, n=10, n=3, n=3
Table 8: Mucoadhesive strength study and in vitro retention time of 5-FU buccal tablets
Formulation batches Mucoadhesive strength (gm) Mucoadhesive force (N) In vitro retention time Swelling index (%)
FT1 11.42±0.10 1.120 8 h 42 min 48.16
FT2 12.86±0.12 1.261 9 h 40 min 53.24
FT3 11.00±0.08 1.079 7 h 50 min 41.23
FT4 11.69±0.61 1.146 9 h 01 min 38.46
FT5 12.82±0.50 1.257 9 h 35 min 43.19
FT6 13.94±0.31 1.367 10 h15 min 58.32
FT7 13.19±0.31 1.293 9 h 55 min 49.17
FT8 12.46±0.31 1.222 9 h 15 min 40.59
FT9 14.56±0.31 1.428 11 h 10 min 62.12
5-FU: 5-fluorouracil
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enormously. In the present study, polymers used in the formulation 
carbopol and PVP have been reported to show good swelling 
properties. These polymers in combination showed good swelling 
properties ranging from 38.46% to 62.12% as shown in Table 8 and 
Fig 4. This increase in swelling was possible only due to imbibitions 
and mucilage formation of polymers when it comes in contact with 
biological and or aqueous medium and due to which swelling took 
place. 
Mucoadhesive strength of buccal patch formulation
Mucoadhesive strength
From the mucoadhesive strength data, it was found that the drug release 
study the patch prepared carbopol in the amount of 100 mg (FP1), 
200 mg (FP2), and 400 mg (FP3) were about 8.70±0.17, 9.10±0.14, 
and 9.56±0.24, respectively. Patch containing PVP in the amount of 
100 mg (FP4), 1200 mg (FP5), and 400 mg (FP6) were about 9.23±0.09, 
14.5±0.70, and 10.6±0.12, respectively.
The patch prepared with carbopol and PVP with the amount of 50 mg 
(FP7) shows maximum mucoadhesive strength of 18.5±0.23. The patch 
prepared with carbopol and PVP with the amount of 100 mg (FP8) 
shows mucoadhesive strength of 14.5±0.23. The patch prepared with 
carbopol and PVP with the amount of 100 mg (FP9) shoes mucoadhesive 
strength of 13.01±0.23 as shown in Table 9 and Fig. 5 [32].
Surface pH of patch
Surface pH was determined by the patch were allowed in contact 
with 1 ml of distilled water. The surface pH was noted by bringing a 
combined glass electrode or pH paper near the surface of patch and 
allowing equilibrate for 1 min and the average surface pH of all patches 
are given in Table 10. From the surface pH data, it was found that patch 
prepared carbopol in amount of 100 mg (F1), 200 mg (F2), 400 mg 
(F3) were about 6.45±0.173, 6.11±0.173, and 6.08±0.173, respectively. 
Patch containing PVP in the amount of 100 mg (F4), 200 mg (F5), and 
400 mg (F6) were about 6.36±0.208, 5.90±0.152, and 7.06±0.200. The 
patch prepared with carbopol and PVP with the amount of 100 mg (F7), 
120 mg (F8), and 80 mg (F9) were about 6.52±0.155, 5.98±0.251, and 
7.32±0.360 [33].
Drug content uniformity of patch
In each case, three patches were used and the average drug content was 
calculated. From the in folding endurance data, it was found that patch 
prepared carbopol in amount of 100 mg (F1), 200 mg (F2), and 400 mg 
(F3) were about 90.3±1.02, 93.0±0.67, and 98.3±0.12, respectively. Patch 
containing PVP in the amount of 100 mg (F4), 200 mg (F5), and 400 mg 
(F6) were about 90.0±0.99, 96.4±0.56, and 94.6±0.98, respectively. The 
patch prepared with carbopol and PVP with the amount of 100 mg (F7), 
120 mg (F8), and 80 mg (F9) were about 99.0±0.19, 97.0±0.49, and 
96.3±0.85 shown in Table 10 [34].
Folding endurance of patch
The folding endurance of the patch was determined by repeatedly 
folding a small strip of the patch at the same place until it broke and 
the average folding endurance of all patch is given in Table 10. From the 
in folding endurance data, it was found that patch prepared carbopol 
in amount of 100 mg (F1), 200 mg (F2), and 400 mg (F3) were about 
>290, >290, >290. Patch containing PVP in amount of 100 mg (F4), 
Fig. 1: Fourier transform infrared, (a) 5-fluorouracil, (b) CP, 
(c) polyvinylpyrrolidone (PVP), (d) complex CP+PVP, (e) sodium 
deoxycholate, (f) tablet formulation
Fig. 2: Fourier transform infrared, (a) 5-fluorouracil, (b) CP, 
(c) polyvinylpyrrolidone, (d) polyvinyl alcohol, (e) patch 
formulation
Fig. 3: Differential scanning calorimeter (a) 5-fluorouracil, (b) CP, 
(c) polyvinylpyrrolidone, (d) complex CP+PVP, (e) buccalpatches 
formulation (PF), (f) buccaltablet formulation (TF)
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200 mg (F5), and 400 mg (F6) were about >290, >290, >290. The patch 
prepared with carbopol and PVP with amount of 100 mg (F7), 120 mg 
(F8), 80 mg (F9) were about >290, >290, >290 [34].
Thickness of patch
The thickness of the patch was measured using vernier caliper and 
the average thickness of all patches is shown in Table 10. Thickness 
of film prepared of carbopol in amount of 100 mg (F1), 2000 mg (F2), 
400 mg (F3) were found to 0.269±0.023, 0.289±0.025, 0.205±0.015. 
Patch containing PVP in amount of 100 mg (F4), 200 mg (F5), and 
400 mg (F6) were found to be 0.260±0.015, 0.348±0.045, 0.256±0.025, 
respectively. The patch prepared with carbopol and PVP with amount 
of 100 mg (F7), 120 mg (F8), and 80 mg (F9) were about 0.370±0.010, 
0.234±0.011, 0.245±0.028 [34].
Weight uniformity of patch
The weight of prepared patch was determined using digital balance 
and the average weights of all patches are given in Table 10. Patch 
prepared carbopol in amount of 100 mg (F1), 200 mg (F2), 400 mg 
(F3) were about 241±2.17, 245±6.42, 263±10.6, respectively. Patch 
containing PVP in amount of 100 mg (F4), 200 mg (F5), and 400 mg 
(F6) were about 278±4.25, 265±1.76, 212±5.78, respectively. The 
patch prepared with carbopol and PVP with amount of 100 mg 
(F7), 120 mg (F8), and 80 mg (F9) were about 282±3.24, 269±2.65, 
277±5.36 [33].
Swelling index
From the swelling index data, it was found that, the drug release study 
the patch prepared carbopol in the amount of 100 mg (F1), 200 mg (F2), 
400 mg (F3) were 16.12±1.32, 16.76±0.95, and 17.40±1.10, respectively. 
Patch containing PVP in amount of 100 mg (F4), 1200 mg (F5), and 
400 mg (F6) were about 18.12±0.76, 18.95±0.89, and 20.05±2.52, 
respectively. The patch prepared with carbopol and PVP with amount 
of 50 mg (F7) shows maximum swelling index of 25.12±1.26. The film 
prepared with carbopol and PVP with amount of 100 mg (F8) shows 
swelling index of 23.51±3.06. The film prepared with carbopol and PVP 
with amount of 100 mg (F9) shows swelling index of 24.01±4.80 shown 
in Table 11 and Fig 6 [32].
TS
From the TS data, it was found that the drug release study the patch 
prepared carbopol in amount of 100 mg (F1), 200 mg (F2), and 400 mg 
(F3) were 220.15, 259.32, and 297.57, respectively. Patch containing 
PVP in amount of 100 mg (F4), 1200 mg (F5), and 400 mg (F6) were 
about 312.45, 320.54, and 337.56, respectively. The patch prepared 
with carbopol and PVP with the amount of 50 mg (F7) shows maximum 
TS of 371.81. The film prepared with carbopol and PVP with amount of 
100 mg (F8) shows TS of 358.66. The patch prepared with carbopol and 
PVP with amount of 100 mg (F9) shows TS of 361.95 shown in Table 11 
and Fig 7 [32].
Table 9: Mucoadhesive strength of formulation










Fig. 5: Mucoadhesive strength of buccal patches
Fig. 6: Swelling index after 1 h
Fig. 7: Tensile strength g/cm2










FP1 6.45±0.173 241±2.17 0.269±0.023 >290 90.3±1.02 3.22±0.56
FP2 6.11±0.173 245±6.42 0.289±0.025 >290 93.0±0.67 4.07±0.86
FP3 6.08±0.173 263±10.6 0.205±0.015 >290 98.3±0.12 4.28±0.46
FP4 6.36±0.208 278±4.25 0.260±0.015 >290 90.0±0.99 3.77±0.33
FP5 5.90±0.152 265±1.76 0.348±0.045 >290 96.4±0.56 3.77±0.33
FP6 7.06±0.200 212±5.78 0.256±0.025 >290 94.6±0.98 4.94±0.54
FP7 6.52±0.155 282±3.24 0.370±0.010 >290 99.0±0.19 3.55±0.99
FP8 5.98±0.251 269±2.65 0.234±0.011 >290 97.0±0.49 3.98±0.33
FP9 7.32±0.360 277±5.36 0.245±0.028 >290 96.3±0.85 4.57±0.33
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In vitro study of buccal tablet
A 32 full factorial design was constructed to study the effect of the amount 
of carbopol 974p (X1) and PVP (X2) on drug release from tablets. The 
dependent variables chosen were drug release and mucoadhesion. In 
drug release study of 5-FU was found to be a function of the polymer 
concentration. It was observed that the variation in concentration of 
polymer from factorial batches FT1 to FT9 have variability on release 
rate of drug. The influence of carbopol 974p and PVP ratio on the 
release of 5-FU from the tablets in phosphate buffer having pH 6.8 at 
37±0.5°C. It is clear that increase in concentration of carbopol 974p 
and PVP in formulae decreased the release rate. The formulation FT-5 
showed the best 99.34% drug release.
Formulations FT-6, FT-7, and FT-9 containing higher concentrations 
of carbopol 974p showed less drug release from 79.61% to 85.42% 
as compared to other formulation batches, out of which batch FT-9 
showed very less drug release due to higher concentrations of 
carbopol 974p and PVP. The formulations FT-1, FT-2 and FT-3 showed 
increase in drug release from 80.76% to 92.46% due to decrease in 
concentration of carbopol 974p and PVP. The Formulations FT-4, FT-5, 
and FT-8 showed drug release from 75.10% to 99.34%, in which the 
polymer concentration was found optimum in batch F-3 which showed 
drug release up to 99.34%. The batch FT-4 showed less drug release. 
Cumulative drug release buccal tablet shown in Fig. 8.
Final equation in terms of coded factors
% Drug release = +97.48-6.06* A-2.16* B-6.82* AB-10.52* A2-13.46* B2
In vitro study of buccal patch
From the in vitro dissolution data, it was found that the drug release study 
the patch prepared Carbopol in amount of 100 mg (FP1), 200 mg (FP2), 
400 mg (FP3) were about 73.07±0.72%, 60.06±0.68%, 76.61±0.32% 
drug release, respectively. Patch containing PVP in amount of 100 mg 
(FP4), 200 mg (FP5), and 400 mg (FP6) were about 59.54±0.55%, 
58.41±0.52%, 54.27±0.51% drug relSease, respectively. The patch 
prepared with carbopol and PVP with Amount of 100 mg (FP7) shows 
maximum dissolution of 81.43±0.54. The patch prepared with carbopol 
in amount of 100 mg with PVA in 50 mg (FP8) shows dissolution of 
71.84±0.69%. The patch prepared with carbopol in amount of 50 mg with 
PVA in 100 mg (FP9) shows dissolution of 67.17±0.74%. From the above 
results, it can be concluded that increasing concentration of polymer that 
is carbopol and PVP increases drug release. Combined effect of carbopol 
and PVP in (1:1) shown much better drug release profile. Cumulative % 
drug release of buccal patches shown in Fig. 9 [16,35].
Ex vivo permeation studies
5-FU permeation from formulations FT-5 across sheep mucosa over 
10 h is shown in Fig 10. The maximum permeation of 5-FU from FT-5 
and FP-5 was 96% and 69% at 10 h and 8 hrs, respectively. Regression 
of the linear portions of the two plots gave slopes and intercepts from 
which the permeation flux (slope divided by mucosal surface area) 
of FT-5 and FP-5 were calculated to be 8.366 and 5.233 mg/cm2/h, 
respectively. While permeation coefficients were found be 2.36 and 
1.43 cm/h for FT-5 and FP-5 formulations, respectively. In formulation 
FT-5 and FP-5 addition of sodium deoxycholate and polyethylene glycol 
increased the cumulative percentage of drug permeated. This may be 
due to sodium deoxycholate and Polyethylene glycol extracted only 
mucosal lipid from the intercellular spaces. Thus, this enhances the 
diffusivity of the 5-FU through the par cellular or polar route, along 
with the extraction of mucosal lipid from the intercellular spaces by 
the formation of micelles. This resulted in enhancing passive diffusivity 
of the 5-FU throughtranscellular (crossing the cell membranes and 
entering the cell) and par cellular routes.
ANOVA analysis for drug release and mucoadhesion
Evaluation and interpretation of research findings are important and 
the p-value serves a valuable purpose in these findings. ANOVA for the 
dependent variables drug release and Mucoadhesion was done. The 
coefficients of X1 and X2 were found to be significant at p<0.05, hence 
confirmed that both the variables have significant effect on the selected 
responses. Overall, both the variables caused significant change in the 
responses. ANOVA and response surface analysis were performed using 
design expert software.
Fig. 7: Tensile strength g/cm2
Fig. 8: Cumulative drug release buccal tablet
Fig. 9: Cumulative % drug release of buccal patches
Table 11: Swelling index and tensile strength
Formulation code Swelling index (% wt 
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Fig. 10: Ex vivo permeation studies of FT-5 and FP-5 formulation
Fig. 11: Predicted versus actual plot of % drug release for tablet formulation
Fig. 12: Predicted versus actual plot of mucoadhesion for tablet formulation
Table 12: Analysis of variance table (Partial sum of squares - Type III)
Source Sum of source Df Mean squares F value p-value Probe>F Observation
Model 1018.76 5 203.75 74.24 0.0024 Significant
A-Carbopol 220.58 1 220.58 80.37 0.0029 Significant
B-Polyvinylpyrilidone 28.04 1 28.04 10.22 0.0495 Significant
AB 186.19 1 186.19 67.84 0.0037 Significant
A2 221.34 1 221.34 80.65 0.0029 Significant
B2 362.61 1 362.61 132.12 0.0014 Significant
Residual 8.23 3 2.74
Core Total 1026.99 8
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Response surface analysis
The quadratic model obtained from the regression analysis was used to 
build a 3-D graphs in which the responses were represented by curvature 
surface as a function of independent variables. The relationship between 
the response and independent variables can be directly visualized from 
the response surface plots presented in Figs. 11-14. Predicted plots 
(Figs. 11 and 12) are representations of the responses for the selected 
factors and shows that the predicted results and practically obtained 
results are similar. Three dimensional (3-D) surface plots (Figs. 13 
and 14) for the obtained responses were drawn based on the model 
polynomial functions to assess the change of the response surface and 
also indicates that increase in concentration of carbopol decreases 
the % drug release. These plots explain the relationship between the 
dependent and independent variables, i.e., the effects of two factors on 
the response at one time. The response surface analysis for drug release 
and mucoadhesion was studied which showed significant results. The 
Model F-value of 74.24 and 1348.66 for drug release and mucoadhesion 
implies the model is significant. Values of p<0.0500 indicate model 
terms are significant. The results are shown in Tables 12-15.
Final equation in terms of actual factors
% Drug Release=+25.61528+5.38322* Carbopol+7.21233* 
Polyvinylpyrilidone-0.12129* Carbopol* Polyvinylpyrilidone-0.18702* 
Carbopol2-0.23938* Polyvinylpyrilidone2
Final equation in terms of coded factors
Mucoadhesion=+12.78+1.26* A+0.18* B+0.52* AB-0.080* A2-0.100* B2




From the equation for dissolution, the information conveyed was: 
R2 was high indicating the adequate fitting of the quadratic model. 
As carbopol and polyvinylpyrolidone (−ve coefficient) showed −ve 
Table 13: Standard deviation, mean and R2 for dissolution
Std.Dev 1.66 0.75 R2 0.9920
Mean 81.49 92.30 Adj R-Squared 0.9786
C.V.% 2.03 0.82 Pred R-Squared 0.9382
PRESS 63.52 13.96 Adeq Precision 28.856
Table 14: Analysis of variance table (Partial sum of squares - Type III)
Source Sum of source Df Mean squares F value p-value Probe>F Observation
Model 10.86 5 2.17 1348.66 <0.0001 Significant
A-Carbopol 9.58 1 9.58 5943.77 <0.0001 Significant
B-Polyvinylpyrilidone 0.19 1 0.19 120.66 0.0016 Significant
AB 1.06 1 1.06 658.49 0.0001 Significant
A2 0.013 1 0.013 7.94 0.0668 Significant
B2 0.020 1 0.020 12.41 0.0388 Significant
Residual 4.833E-003 3 1.611E-003
Core total 10.87 8
Fig. 13: 3D graph of % drug release for tablet formulation
Table 15: Standard deviation, mean and R2 for mucoadhesion
Std.Dev 0.040 0.75 R-Squared 0.9996
Mean 12.66 92.30 Adj R-Squared 0.9988
C.V. % 0.32 0.82 Pred R-Squared 0.9962
Press 0.042 13.96 Adeq Precision 108.524
Table 16: Summary of mean pharmacokinetic parameters for 










1 Cmax (ng/ml) 215 231 227
2 T max (h) 3 8 4
3 AUC0-∞ (ng.h/ml) 2534 2754 1603
4 Slope −3.865 −4.119 −0.351
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sign it also indicated that drug delivery system gained more control 
over the release from prepared dosage form. From the equation 
for mucoadhesion, the information conveyed was: R2 was high 
indicating the adequate fitting of the quadratic model. As carbopol and 
polyvinylpyrolidone (+ve coefficient) showed +ve sign it also indicated 
that drug delivery system gained more mucoadhesion. Graphical 
presentation of data shows relationship between response and 
independent variables. The information given by graph was similar 
to that of mathematical equations obtained from statistical analysis. 
The response surface plots showed that various combinations of 
independent variables X1 and X2 satisfy specific requirement (i.e. drug 
release with mucoadhesion while taking into consideration of various 
factors involved in dosage form).
ANOVA for response surface quadratic model (For 
mucoadhesion study)
In vivo study
Six male New Zealand white rabbits (2.6 kg) were selected for the in vivo 
study. The dose of 5-FU was adjusted based on the rabbit weight and the 
optimized formulations were cut and placed in the buccal membrane 
with the help of a clip and tablets placed in the buccal membrane with 
the adhesive layer. The results are shown in Table 16.
Stability study of optimized batch
Stability study was done to see the effect of temperature and humidity 
on tablets and patches. Storage conditions:
1. Accelerated temperature 40°C±2°C
2. Accelerated temperature at 75% RH±5%.
Time period of 6 months, at intervals of every 1 month, the tablets 
and patches were visually examined for any physical changes, changes 
in hardness, friability, swelling index, mucoadhesion strength, 
mucoadhesion time, and in vitro drug release study. The results 
indicate no significant change in the tablet properties. Hence, it can 
be concluded that the formulated buccal tablets are stable under 
appropriate storage conditions. The results for stability studies are 
shown in Table 17.
CONCLUSION
FTIR and DSC indicating compatibility of the drug and polymers in the 
tablet formulation and patch formulation at molecular level. The drug 
release of buccal tablet showed 75.10–99.34% and buccal patches 
showed 58.41–81.43%. These formulations showed good results when 
compared to the conventional tablet. Formulation of mucoadhesive 
sustained release buccal tablets and patches of 5-FU successfully done 
using different polymers, which would definitely help in increasing 
bioavailability of the drug. ANOVA study showed the “R2” of 0.9943 for 
drug release and 0.9985 for swelling index is in reasonable agreement 
with the “Adj R-Squared” of 0.9849 for drug release and 0.9960 for 
swelling index. The ratio of 29.120 for drug release and 60.670 for 
swelling index indicates an adequate signal. The probablity value, i.e, 
p value found was also less than 0.0500. Therefore, this model can be 
used to develop the design. The desirability result was found equal to 1 
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